Related Experiment Videos
Is it time to include vancomycin for routine perioperative antibiotic prophylaxis in total joint arthroplasty
Eric B Smith1, Rachael Wynne, Ashish Joshi
1Rothman Institute of Orthopedics, Thomas Jefferson University Hospital, Philadelphia, Philadelphia 19107, USA.
Abstract:
In an effort to reduce methicillin-resistant Staphylococcus aureus (MRSA) and overall periprosthetic joint infections (PJI), we switched the perioperative prophylactic antibiotic during total knee arthroplasty and total hip arthroplasty from cefazolin to vancomycin in June 2008. We retrospectively reviewed the total and MRSA PJI in 5036 primary total joint arthroplasties, as well as the cure rate of PJI from January 2006 to June 2008 (Ancef Period) and June 2008 to December 2010 (Vanco Period). With vancomycin, total PJI was significantly reduced (1.0%-0.5%) and MRSA PJI (0.23%-0.07%). Periprosthetic joint infections that occurred were more successfully treated with irrigation and debridement only, not requiring spacer (76.9% vs 22.2%). The use of vancomycin as the perioperative prophylactic antibiotic for primary total joint arthroplasties appeared to be effective in decreasing the rate of PJI and may result, when they occur, in infections with less virulent organisms.
Insights
Switching to vancomycin for joint replacement surgery significantly reduced periprosthetic joint infections (PJI), including MRSA PJI. Infections treated during the vancomycin period were also more successfully managed, often avoiding the need for spacers.
Area of Science:
- Orthopedic Surgery
- Infectious Disease
- Pharmacology
Background:
- Periprosthetic joint infections (PJI) are a significant complication following total knee arthroplasty (TKA) and total hip arthroplasty (THA).
- Methicillin-resistant Staphylococcus aureus (MRSA) is a common pathogen causing PJI, often requiring complex treatment.
- Cefazolin was the standard prophylactic antibiotic, but concerns about efficacy against certain pathogens prompted a change.
Purpose of the Study:
- To evaluate the impact of switching perioperative prophylactic antibiotics from cefazolin to vancomycin on PJI rates.
- To assess the effect of this antibiotic change on MRSA PJI rates.
- To compare the treatment outcomes of PJI before and after the antibiotic switch.
Main Methods:
- Retrospective review of 5036 primary TKA and THA procedures.
- Comparison of PJI rates and types between the cefazolin (Ancef Period: Jan 2006-June 2008) and vancomycin (Vanco Period: June 2008-Dec 2010) eras.
- Analysis of PJI cure rates, specifically focusing on outcomes requiring surgical intervention like spacers.
Main Results:
- Total PJI rates decreased significantly from 1.0% to 0.5% after switching to vancomycin.
- MRSA PJI rates showed a marked reduction from 0.23% to 0.07%.
- PJI cases in the vancomycin period were more successfully treated with irrigation and debridement alone (76.9% vs 22.2%), with fewer requiring spacers.
Conclusions:
- Vancomycin is an effective perioperative prophylactic antibiotic for primary total joint arthroplasty, significantly reducing overall and MRSA PJI.
- The use of vancomycin may lead to PJI caused by less virulent organisms, improving treatment outcomes.
- This antibiotic stewardship change demonstrates a positive impact on patient safety and surgical outcomes in joint replacement procedures.
Related Concept Videos
01:18Endocarditis III: Medical Management
01:29Endocarditis IV: Nursing Management
01:22Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
01:25Clinical Significance of Antibiotic Resistance
00:57Antibiotic Selection
01:28Antimicrobial Effectiveness